Algernon Pharmaceuticals updates Phase 2 human testing of NP-120 (Ifenprodil) for COVID-19

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update on protocol planned for a physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea.

Moreau telling Proactive how they are fast-tracked for this trial and what the next steps will be.


Click the image above to see interview

Share via
Copy link
Powered by Social Snap